Table of Contents
Foods high in tyramine — aged cheeses, cured meats, fermented foods, red wine, beer — can theoretically trigger catecholamine release. Stimulant medications, decongestants, cocaine, amphetamines, and certain herbal supplements should be avoided. Beta-blockers should not be taken without prior alpha-blockade. Patients awaiting surgery should discuss all medications and supplements with their endocrinologist.
21 How long does pre-operative preparation take?
Most guidelines recommend a minimum of 10 to 14 days of alpha-adrenergic blockade before surgery, though some centers extend this to four weeks for better blood pressure control and plasma volume expansion. The goal is to achieve normotension, eliminate paroxysmal attacks, and allow a postural drop in blood pressure — signifying adequate alpha-blockade and volume repletion.
22 What happens in the operating room that makes phlebectomy surgery risky?
Tumor manipulation during surgery — including laparoscopic insufflation, direct handling, and ligation of tumor vessels — can cause abrupt, massive catecholamine release, producing severe hypertensive crises. Conversely, once the adrenal vein is ligated and the tumor is removed, catecholamine levels drop precipitously, potentially causing profound hypotension. Expert anesthetic management with continuous arterial monitoring and vasoactive drugs is essential.
23 Will blood pressure normalize after surgery?
In the majority of patients, blood pressure normalizes or significantly improves after successful tumor resection. However, approximately 25–50% of patients with pre-existing hypertension remain hypertensive post-operatively — likely because chronic catecholamine excess has induced structural and functional vascular changes. Blood pressure medications may still be required, though often at lower doses.
24 How is malignant pheochromocytoma treated?
Treatment of malignant PPGL is complex and ideally managed at specialist centers. Surgical debulking of accessible metastases may improve symptom control. 131I-MIBG therapy is effective for MIBG-avid disease. PRRT with 177Lu-DOTATATE benefits somatostatin receptor-expressing tumors. Chemotherapy (CVD protocol) offers moderate response rates. Kinase inhibitors (sunitinib) and immunotherapy are under active investigation in clinical trials.
25 What is the prognosis for pheochromocytoma?
For localized, non-malignant pheochromocytoma treated surgically, the prognosis is excellent — most patients are cured. Five-year survival rates exceeding 95% are reported for benign disease. For malignant pheochromocytoma, prognosis is more variable: five-year survival ranges from approximately 40–77% depending on the extent of disease, genotype, and availability of effective therapy. SDHB-mutated malignant pheochromocytoma carries the most guarded prognosis.
26 Can pheochromocytoma recur after successful surgery?
Yes. Recurrence rates of approximately 6–17% over ten years are reported for apparently benign pheochromocytoma. The risk is substantially higher for hereditary cases, bilateral tumors, extra-adrenal disease, and those with SDHB mutations. This is why lifelong annual biochemical surveillance is recommended for all patients, regardless of apparently successful surgical cure.
27 What should family members of a patient with pheochromocytoma do?
If a germline (hereditary) mutation is identified in the patient, first-degree biological relatives — parents, siblings, and children — should be offered genetic counselling and cascade genetic testing. Those who carry the same mutation require personalized surveillance protocols, which vary depending on the specific gene involved and may include periodic biochemical testing and imaging from a young age.
28 Is a biopsy used to diagnose pheochromocytoma?
Percutaneous (needle) biopsy of a suspected pheochromocytoma is generally contraindicated due to the risk of triggering a life-threatening catecholamine surge. The diagnosis is established biochemically (elevated metanephrines) and radiologically (characteristic imaging features), without requiring tissue sampling before surgical resection. Post-operative histopathology then confirms the diagnosis.
29 What are the PASS score and GAPP score?
The PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and GAPP (Grading system for Adrenal Pheochromocytoma and Paraganglioma) are histopathological scoring systems applied by pathologists to tumor specimens to estimate malignant potential. Neither is perfectly predictive, but they provide supplementary prognostic information and help guide surveillance intensity after surgery.
30 Where can patients find specialist care and support?
Patients with pheochromocytoma should ideally be managed at centres with multidisciplinary endocrine tumor teams including endocrinologists, urologists or surgeons with specific pheo experience, specialist anaesthetists, pathologists, and genetic counsellors. Support organisations such as the Pheo Para Alliance provide patient education, peer networks, and guidance on accessing specialised care internationally.
Medical Disclaimer:
The information provided on this website is for general educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
